EN PL
 
EN PL
Bieżący numer
Archiwum
Online first
O czasopiśmie
Dla autorów
Książki i Konferencje
4/2011 vol. 49
Pobierz cytowanie
PRACA PRZEGLĄDOWA
Zastosowanie leków biologicznych w terapii tocznia rumieniowatego układowego
Justyna Kramza
,
 
Eugeniusz J. Kucharz
 
 
 
Więcej
Ukryj
 
Data publikacji online: 30-08-2011
 
 
Reumatologia 2011;49(4):264-274
 
Artykuł (PDF)
Referencje (56)
 
SŁOWA KLUCZOWE
toczeń rumieniowaty układowy
leki biologiczne
 
STRESZCZENIE
Toczeń rumieniowaty układowy (systemic lupus erythematosus – SLE) jest chorobą autoimmunologiczną o nieznanej etiologii. Duża skuteczność leków biologicznych stosowanych u chorych na reumatoidalne zapalenie stawów skłania do poszukiwania leków biologicznych, które umożliwiają leczenie chorych na SLE. Badane są różne przeciwciała: przeciwko rozpuszczalnemu czynnikowi stymulującemu limfocyty B ( B lymphocyte stimulator – BLyS) (belimumab, briobacept, atacicept), przeciwko limfocytom B (rytuksymab, okrelizumab, epratuzumab), hamujące kostymulację limfocytów T (abatacept), tolerogeny, interferon oraz inne. Mimo niektórych zachęcających wyników żaden z tych leków nie znalazł zastosowania w praktyce klinicznej.
 
REFERENCJE (56)
1.
Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009; 158: 155-163. .
Google Scholar
 
 
2.
Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-2459. .
Google Scholar
 
 
3.
Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-1178. .
Google Scholar
 
 
4.
Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62: 201-210. .
Google Scholar
 
 
5.
Merrill JT, Wallace DJ, McKay J, et al. Long-term safety profile of belimumab (fully human monoclonal antibody to BLys) in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis 2008; 67: 217. .
Google Scholar
 
 
6.
Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-4150. .
Google Scholar
 
 
7.
Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-475. .
Google Scholar
 
 
8.
Chehab G, Sander O, Fischer-Betz R, Schneider M. Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus. Z Rheumatol 2007; 66: 328, 330-336. .
Google Scholar
 
 
9.
Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589. .
Google Scholar
 
 
10.
Lindholm C, Börjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35: 826-833. .
Google Scholar
 
 
11.
Gunnarsson I, Sundelin B, Jónsdóttir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272. .
Google Scholar
 
 
12.
van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004; 33: 423-427. .
Google Scholar
 
 
13.
Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24: 3717-3723. .
Google Scholar
 
 
14.
Armstrong DJ, McCarron MT, Wright GD. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 2006; 26: 771-772. .
Google Scholar
 
 
15.
Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982. .
Google Scholar
 
 
16.
Niaz FA, Aleem A. Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transpl 2010; 21: 109-112. .
Google Scholar
 
 
17.
Kamiya K, Kurasawa K, Arai S, et al. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol 2010; 20: 81-85. .
Google Scholar
 
 
18.
Hundae A, Peskoe S, Grimsley E, Patel S. Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. South Med J 2008; 101: 943-944. .
Google Scholar
 
 
19.
Lehembre S, Macario-Barrel A, Musette P, et al. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol 2006; 133: 53-55. .
Google Scholar
 
 
20.
Perrotta S, Locatelli F, La Manna A, et al. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002; 116: 465-467. .
Google Scholar
 
 
21.
Risselada AP, Kallenberg CG. Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford) 2006; 45: 915-916. .
Google Scholar
 
 
22.
Pego-Reigosa JM, Lu TY, Fontanillo MF, et al. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology (Oxford) 2010; 49: 691-696. .
Google Scholar
 
 
23.
Hickman RA, Denniston AK, Yee CS, et al. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy. Lupus 2010; 19: 327-329. .
Google Scholar
 
 
24.
Todd DJ, Costenbader KH. Dyspnoea in a young woman with active systemic lupus erythematosus. Lupus 2009; 18: 777-784. .
Google Scholar
 
 
25.
Kittaka K, Dobashi H, Baba N, et al. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab. Scand J Rheumatol 2008; 37: 390-393. .
Google Scholar
 
 
26.
Ahn ER, Lander G, Bidot CJ, et al. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant following rituximab therapy. Am J Hematol 2005; 78: 127-129. .
Google Scholar
 
 
27.
Petschner F, Walker UA, Schmitt-Gräff A, et al. “Catastrophic systemic lupus erythematosus” with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab. Dtsch Med Wochenschr 2001; 126: 998-1001. .
Google Scholar
 
 
28.
Lim SW, Gillis D, Smith W, et al. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern Med J 2006; 36: 260-262. .
Google Scholar
 
 
29.
Torrente-Segarra V, Lisbona-Pérez M, Rotes-Sala D, et al. Clinical, biological and ultrasonographic remission in a patient with musculoskeletal systemic lupus erythematosus with rituximab. Lupus 2009; 18: 270-272. .
Google Scholar
 
 
30.
Polido-Pereira J, Ferreira D, Rodrigues AM, et al. Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci 2009; 1173: 712-720. .
Google Scholar
 
 
31.
Podolskaya A, Stadermann M, Pilkington C, et al. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008; 93: 401-406. .
Google Scholar
 
 
32.
Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr 2010; 99: 967-974. .
Google Scholar
 
 
33.
Ramos-Casals M, Brito-Zerón P, Mun~oz S, Soto MJ; BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune disease. Medicine 2008; 87: 345-364. .
Google Scholar
 
 
34.
Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61: 482-487. .
Google Scholar
 
 
35.
Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-1545. .
Google Scholar
 
 
36.
Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677. .
Google Scholar
 
 
37.
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233. .
Google Scholar
 
 
38.
Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458-2466. .
Google Scholar
 
 
39.
Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) Clinical trials.com .
Google Scholar
 
 
40.
Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) Clinical trials.com .
Google Scholar
 
 
41.
Petri M, et al. Clinically meaningful improvements with epratuzumab (anti-CD22 mAb targeting B-cells) in patients (Pts) with moderate/severe SLE flares: results from 2 randomized controlled trials. Arthritis Rheum 2008; 58 (Suppl 9): S571. American College of Rheumatology (ACR) Annual Scientific Meeting, October 24-29, 2008; San Francisco, USA. .
Google Scholar
 
 
42.
Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005; 102: 15178-15183. .
Google Scholar
 
 
43.
Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 3077-3087. .
Google Scholar
 
 
44.
Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008; 58: 2470-2480. .
Google Scholar
 
 
45.
Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178-181. .
Google Scholar
 
 
46.
Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43: 1431-1442. .
Google Scholar
 
 
47.
Niewold TB, Hua J, Lehman TJ, et al. High serum IFN- activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492-502. .
Google Scholar
 
 
48.
Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an antiinterferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785-1796. .
Google Scholar
 
 
49.
Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542-552. .
Google Scholar
 
 
50.
Matsumura R, Umemiya K, Sugiyama T, et al. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 2009; 27: 416-421. .
Google Scholar
 
 
51.
Takahashi N, Naniwa T, Banno S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol 2008; 18: 72-75. .
Google Scholar
 
 
52.
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161-3169. .
Google Scholar
 
 
53.
Aringer M, Steiner G, Graninger WB, et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274-279. .
Google Scholar
 
 
54.
Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009; 18: 690-697. .
Google Scholar
 
 
55.
Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-αlpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451-1454. .
Google Scholar
 
 
56.
Soforo E, Baumgartner M, Francis L, et al. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2010; 37: 204-205.
Google Scholar
 
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
Wyślij mailem
ARTYKUŁ POWIĄZANY
Artykuł oryginalny/Original paper
Wkład Instytutu Reumatologii w rozwój badań nad toczniem rumieniowatym układowym w latach 1963–2002
ARTYKUŁ PRZEGLĄDOWY
Przeciwciała przeciwko rybosomalnemu białku P – znaczenie kliniczne i udział w patogenezie tocznia rumieniowatego układowego
ARTYKUŁ PRZEGLĄDOWY/REVIEW PAPER
Zajęcie układu krążenia u chorych na toczeń rumieniowaty układowy – przegląd literatury i własne obserwacje. Serologiczne czynniki ryzyka powikłań kardiologicznych
ARTYKUŁ PRZEGLĄDOWY/REVIEW PAPER
Ocena przydatności różnych przeciwciał antyfosfolipidowych w diagnostyce wtórnego zespołu antyfosfolipidowego w przebiegu tocznia rumieniowatego układowego – przegląd literatury i obserwacje własne
Opis przypadku
Współistnienie ziarniniaka Wegenera i tocznia rumieniowatego układowego – opis przypadku z dyskusyjnym rozpoznaniem
Indeksy
 
Indeks słów kluczowych
Indeks dziedzin
Indeks autorów
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
© 2006-2024 Journal hosting platform by Bentus
Scroll to top